Capecitabine-loaded nanoniosomes and evaluation of anticancer efficacy

References

• Abdulla M, Shukla S. Dietary aspects in cancer prevention-A mini-Review. In:Atroshi F, editor. Pharmacology and nutritional Intervention in the treatment of disease. England: InTech; 2014.
   Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• De La Cruz L, Blankenship SA, Chatterjee A, et al. Outcomes after oncoplastic breast-conserving surgery in breast cancer patients: a systematic literature review. Ann Surg Oncol. 2016;23:3247–3258.
   PubMed Web of Science ®Google Scholar
• Heidari M, Sattarahmady N, Azarpira N, et al. Photothermal cancer therapy by gold-ferrite nanocomposite and near-infrared laser in animal model. Lasers Med Sci. 2016;31:221–227.
   PubMed Web of Science ®Google Scholar
• Tomuleasa C, Soritau O, Orza A, et al. Gold nanoparticles conjugated with cisplatin/doxorubicin/capecitabine lower the chemoresistance of hepatocellular carcinoma-derived cancer cells. J. Gastrointestin. Liver Dis. 2012;21:187–196.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol. 2000;18:1337–1345.
   PubMed Web of Science ®Google Scholar
• Devanaboyina N, Kishore YS, Pushpalatha P, et al. Development and validation of new RP HPLC method for analysis of capecitabine in pharmaceutical dosage form. Int J Sci Inv Today. 2013;2:21–30.
   Google Scholar
• Satake H, Iwatsuki M, Uenosono Y, et al. Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104). Cancer Chemother Pharmacol. 2017;79:147–153.
   PubMed Web of Science ®Google Scholar
• Sun SB, Liu P, Shao FM, et al. Formulation and evaluation of PLGA nanoparticles loaded capecitabine for prostate cancer. Int J Clin Exp Med. 2015;8:19670–19681.
   PubMed Web of Science ®Google Scholar
• Vincent MD, Breadner D, Soulieres D, et al. Phase II trial of capecitabine plus erlotinib versus capecitabine alone in patients with advanced colorectal cancer. Future Oncol. 2017;13:777–786.
   PubMed Web of Science ®Google Scholar
• Chang EH, Harford JB, Eaton MAW, et al. Nanomedicine: past, present and future - a global perspective. Biochem Biophys Res Commun. 2015;468:511–517.
   PubMed Web of Science ®Google Scholar
• Sattarahmady N, Azarpira N, Hosseinpour A, et al. Albumin coated arginine-capped magnetite nanoparticles as a paclitaxel vehicle: physicochemical characterizations and in vitro evaluation. J Drug Deliv Sci Technol. 2016;36:68–74.
   Web of Science ®Google Scholar
• Heli H, Mirtorabi S, Karimian K. Advances in iron chelation: an update. Expert Opin Ther Pat. 2011;21:819–856.
   PubMed Web of Science ®Google Scholar
• Nazari-Vanani R, Azarpira N, Heli H, et al. A novel self-nanoemulsifying formulation for sunitinib: evaluation of anticancer efficacy. Colloids Surf B Biointerfaces. 2017;160:65–72.
   PubMed Web of Science ®Google Scholar
• Negahdary M, Heli H. Applications of nanoflowers in biomedicine. Recent Pat Nanotechnol. 2018;12:22–33.
   PubMed Web of Science ®Google Scholar
• Sattarahmady N, Firoozabadi V, Nazari-Vanani R, et al. Investigation of amyloid formation inhibition of chemically and biogenically from Citrus aurantium L. blossoms and Rose damascena oils of gold nanoparticles: toxicity evaluation in rat pheochromocytoma PC12 cells. Int J Biol Macromol. 2018;112:703–711.
   PubMed Web of Science ®Google Scholar
• VorinostatKwak TW, Kim DH, Jeong YI, et al. Antitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cells. J Nanobiotechnol. 2015;13:60–73.
   PubMed Web of Science ®Google Scholar
• Kumar A. Leishmania and leishmaniasis. New York: Springer; 2013.
   Google Scholar
• Barakat HS, Kassem MA, El-Khordagui LK, et al. Vancomycin-eluting niosomes: a new approach to the inhibition of staphylococcal biofilm on abiotic surfaces. AAPS PharmSciTech. 2014;15:1263–1274.
   PubMed Web of Science ®Google Scholar
• Guan L, Liu X, Xiao F, et al. Characterization of elastic niosomes prepared with various nonionic surfactants for lidocaine hydrochloride transdermal delivery. Nanosci Nanotechnol Lett. 2016;8:1033–1039.
   Web of Science ®Google Scholar
• Shaker DS, Shaker MA, Hanafy MS. Cellular uptake, cytotoxicity and in-vivo evaluation of Tamoxifen citrate loaded niosomes. Int J Pharm. 2015;493:285–294.
   PubMed Web of Science ®Google Scholar
• Shirsand S, Para M, Nagendrakumar D, et al. Formulation and evaluation of Ketoconazole niosomal gel drug delivery system. Int J Pharm Investig. 2012;2:201–207.
   PubMedGoogle Scholar
• Asgharkhani E, Azarbayjani A.F, Irani S, et al. Artemisinin-loaded niosome and pegylated niosome: physico-chemical characterization and effects on MCF-7 cell proliferation. J Pharm Investig. 2018;48:251–256
   Google Scholar
• Zarei M, Norouzian D, Honarvar B, et al. Paclitaxel loaded niosome nanoparticle formulation prepared via reverse phase evaporation method: an in vitro evaluation. Pak J Biol Sci. 2013;16:295–298.
   PubMedGoogle Scholar
• Kanaani L, Tabrizi MM, Khiyavi AA, et al. Improvement the efficacy of cisplatin by niosome nanoparticles against human breast cancer cell line BT-20: an in vitro study. Asian Pac J Cancer Biol. 2017;2:25–26.
   Google Scholar
• Sharma PK, Saxena P, Jaswanth A, et al. Novel encapsulation of lycopene in niosomes and assessment of its anticancer activity. J Bioequiv Availab. 2016;8:224–232.
   Google Scholar
• Jyoti K, Pandey RS, Madan J, et al. Inhalable cationic niosomes of curcumin enhanced drug delivery and apoptosis in Lung cancer cells. Indian J Pharm Educ Res. 2016;50:21–31.
   Web of Science ®Google Scholar
• Babaei M, Ardjmand M, Akbarzadeh A, et al. Efficacy comparison of nanoniosomal and pegylated nanoniosomal Cisplatin on A172 cell line. Tissue Eng Regen Med. 2014;11:350–354.
   Web of Science ®Google Scholar
• Mehrabi MR, Norouzian D, Shokrgozar MA, et al. Pegylated niosomal nanoparticles loaded with vincristine: characterization and in vitro evaluation. Trop J Pharm Res. 2017;16:975–980.
   Web of Science ®Google Scholar
• He RX, Ye X, Li R, et al. PEGylated niosomes-mediated drug delivery systems for Paeonol: preparation, pharmacokinetics studies and synergistic anti-tumor effects with 5-FU. J Liposome Res. 2017;27:161–170.
   PubMed Web of Science ®Google Scholar
• Amiri B, Ahmadvand H, Farhadi A, et al. Delivery of vinblastine-containing niosomes results in potent in vitro/in vivo cytotoxicity on tumor cells. Drug Dev Ind Pharm. 2018;44:1371–1376.
   PubMed Web of Science ®Google Scholar
• Behroozah A, Mazloumi Tabrizi M, Kazemi SM, et al. Evaluation the anti-cancer effect of PEGylated nano-niosomal gingerol, on breast cancer cell lines (T47D), in-Vitro. Asian Pacific J Cancer Prevention. 2018;19:645–648.
   PubMedGoogle Scholar
• Sharma V, Anandhakumar S, Sasidharan M. Self-degrading niosomes for encapsulation of hydrophilic and hydrophobic drugs: an efficient carrier for cancer multi-drug delivery. Mater Sci Eng C. 2015;56:393–400.
   PubMed Web of Science ®Google Scholar
• Hong M, Zhu S, Jiang Y, et al. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. J Control Release. 2009;133:96–102.
   PubMed Web of Science ®Google Scholar
• Palozza P, Muzzalupo R, Trombino S, et al. Solubilization and stabilization of beta-carotene in niosomes: delivery to cultured cells. Chem Phys Lipids. 2006;139:32–42.
   PubMed Web of Science ®Google Scholar
• Gude RP, Jadhav MG, Rao SGA, et al. Effects of niosomal cisplatin and combination of the same with theophylline and with activated macrophages in murine B16F10 melanoma model. Cancer Biother Radiopharm. 2002;17:183–192.
   PubMed Web of Science ®Google Scholar
• Tavano L, Muzzalupo R, Mauro L, et al. Transferrin-conjugated pluronic niosomes as a new drug delivery system for anticancer therapy. Langmuir. 2013;29:12638–12646.
   PubMed Web of Science ®Google Scholar
• Das MK, Kumar R. Development of curcumin nanoniosomes for skin cancer chemoprevention. Int J ChemTech Res. 2015;7:747–754.
   Google Scholar
• Gaikwad SY, Jagtap AG, Ingle AD, et al. Antimetastatic efficacy of niosomal pentoxifylline and its combination with activated macrophages in murine B16F10 melanoma model. Cancer Biother Radiopharm. 2000;15:605–615.
   PubMed Web of Science ®Google Scholar
• Ghadiri M, Vasheghani-Farahani E, Atyabi F, et al. In-vitro assessment of magnetic dextran-Spermine nanoparticles for capecitabine delivery to cancerous cells. Int J Pharm Res. 2017;16:1320–1334.
   Google Scholar
• Pandey S, Mattha Vijayendra Swamy S, Mansha Ubaid Ulla U, et al. Cell line and augument cellular uptake study of statistically optimized sustained release capecitabine loaded Eudragit S100/PLGA (poly (lacticco-glycolic acid)) nanoparticles for colon targeting. Curr Drug Deliv. 2017;14:887–899.
   PubMed Web of Science ®Google Scholar
• Gong X, Moghaddam MJ, Sagnella SM, et al. Lamellar crystalline self-assembly behaviour and solid lipid nanoparticles of a palmityl prodrug analogue of Capecitabine-A chemotherapy agent. Colloids Surf B Biointerfaces. 2011;85:349–359.
   PubMed Web of Science ®Google Scholar
• Payghan SA. Design of three-factor response surface optimization of camouflaged capecitabine nanoerythrovesicles. Asian J Pharm. 2016;10:306–321.
   Web of Science ®Google Scholar
• Kakkar S, Kaur IP. Spanlastics - a novel nanovesicular carrier system for ocular delivery. Int J Pharm. 2011;413:202–210.
   PubMed Web of Science ®Google Scholar